Epilepsy Drugs Global Market Report 2024 by The Business Research Company | Pfizer Inc, SK Biopharmaceuticals, Sanofi, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, H. Lundbeck, Viatris, Otsuka America Pharmaceutical Inc, Bausch Health Companies

The epilepsy drugs market size has grown strongly in recent years. It will grow from $9.59 billion in 2023 to $10.34 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to development of antiepileptic drugs, advancements in diagnostic techniques, increased understanding of epilepsy's neurological basis, growing demand for epilepsy treatment, and regulatory approvals for new medications.

The epilepsy drugs market size is expected to see rapid growth in the next few years. It will grow to $14.03 billion in 2028 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to expansion of personalized medicine, adoption of novel drug delivery methods, emergence of digital health solutions, increased investment in R&D, and integration of AI and ML. Major trends in the forecast period include shift towards combination therapies, rise of telemedicine, focus on drug-resistant epilepsy, integration of genetic testing, and utilization of wearable devices.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=15564&type=smp

Epilepsy Drugs Market Major Segments
The epilepsy drugs market covered in this report is segmented -

1) By Seizure Type: Focal Seizures, Generalized Seizures, Non-Epileptic Seizures
2) By Generation Type: First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics
3) By Route Of Administration: Oral, Intravenous, Intra-Muscular
4) By Distribution Channel: Drug Stores And Retail Pharmacies, Hospital Pharmacies

Key Driver - Car-Sharing And Ride-Hailing Services Fueling The Car Subscription Market's Growth

The rising in number of people affected with epilepsy is expected to propel the growth of the epilepsy drug market going forward. Epilepsy refers to a neurological disorder characterized by recurrent seizures, which can vary in severity and impact on daily life. Epilepsy is more prevalent in older age group and survivors of traumatic brain injuries (TBIs), strokes, brain tumors, and other neurological conditions are at higher risk of developing epilepsy. Epilepsy drugs work by stabilizing electrical activity in the brain, reducing the likelihood and severity of seizures, thus helping to manage and control epilepsy. For instance, in February 2024, according to the world health organization, a US-based national agency, worldwide, approximately 5 million individuals receive an epilepsy diagnosis annually, with high-income countries reporting an estimated 49 cases per 100,000 people annually, while in low- and middle-income nations, this rate can soar to 139 cases per 100,000. Therefore, the rising in number of people affected with epilepsy is driving the growth of the epilepsy drug market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=15564&type=smp

Prominent Trend - Advancements In Epilepsy Treatment Solutions By Leading Pharmaceutical Companies

Major companies operating in the epilepsy drug market are focused on developing innovative treatments to improve seizure control and enhance patient quality of life. Innovative epilepsy treatments may include novel drug formulations, advanced neurostimulation techniques, precision medicine approaches tailored to individual patients, gene therapies, and emerging technologies such as closed-loop systems for seizure detection and intervention. For instance, in January 2024, Akumentis Healthcare, an India-based pharmaceutical company, launched Clasepi, a prescription cannabidio*l (CB*D) drug specifically formulated to treat seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older. It is approved by the Drug Controller General of India (DCGI) and has demonstrated efficacy in reducing seizures, particularly in cases where conventional anti-seizure medications have been ineffective.

Epilepsy Drugs Market Players
Major companies operating in the epilepsy drugs market are Pfizer Inc, SK Biopharmaceuticals, Sanofi, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, H. Lundbeck, Viatris, Otsuka America Pharmaceutical Inc, Bausch Health Companies Inc, UCB S.A, Sun Pharmaceutical Industries Ltd, Eisai Co Ltd, Sumitomo Pharma Co Ltd, Jazz Pharmaceuticals plc, Dr. Reddy's Laboratories Ltd, Angelini S.p.a, Amneal Pharmaceuticals, Alkem Laboratories, Sunovion Pharmaceuticals Inc, Upsher-Smith, Zogenix, Neurelis Inc

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the epilepsy drugs market in 2023. The regions covered in the epilepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Epilepsy Drugs Market Report Structure
3. Epilepsy Drugs Market Trends And Strategies
4. Epilepsy Drugs Market - Macro Economic Scenario
5. Epilepsy Drugs Market Size And Growth
…..
27. Epilepsy Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.